Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SRZN 
Surrozen Inc (SRZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: SRZN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $37
1 Year Target Price $37
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.48% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.84M USD | Price to earnings Ratio - | 1Y Target Price 37 |
Price to earnings Ratio - | 1Y Target Price 37 | ||
Volume (30-day avg) 2 | Beta 0.63 | 52 Weeks Range 5.90 - 18.17 | Updated Date 10/26/2025 |
52 Weeks Range 5.90 - 18.17 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -132.3% | Operating Margin (TTM) -917.29% |
Management Effectiveness
Return on Assets (TTM) -21.93% | Return on Equity (TTM) -62.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35137788 | Price to Sales(TTM) 9.34 |
Enterprise Value 35137788 | Price to Sales(TTM) 9.34 | ||
Enterprise Value to Revenue 2.78 | Enterprise Value to EBITDA 0.71 | Shares Outstanding 8570355 | Shares Floating 4798285 |
Shares Outstanding 8570355 | Shares Floating 4798285 | ||
Percent Insiders 4.09 | Percent Institutions 71.27 |
Upturn AI SWOT
Surrozen Inc
Company Overview
History and Background
Surrozen, Inc. was a preclinical biopharmaceutical company focused on discovering and developing novel regenerative medicines with a focus on specific Wnt proteins. Founded in 2016, Surrozen leveraged its proprietary SWAPu2122 technology to engineer proteins that activate the Wnt pathway, crucial for tissue regeneration. In February 2024, Surrozen was acquired by Twin Ridge Capital Acquisition Corp., and now trades under a new ticker (TRCA).
Core Business Areas
- Regenerative Medicine Development: Focused on developing treatments to repair and regenerate tissues, addressing various diseases and conditions with unmet medical needs.
Leadership and Structure
Before its acquisition, Surrozen was led by a management team with experience in drug development and biotechnology. The organizational structure was typical of a preclinical biotech company, with research and development as core functions.
Top Products and Market Share
Key Offerings
- SZN-1326: A preclinical anti-RSPO3 antibody designed to block Wnt negative feedback in inflammatory bowel disease (IBD) and other indications. It reached Phase 1 clinical trials before the company's acquisition. Market share data is not applicable as it was preclinical. Competitors in the IBD space include companies developing anti-TNF antibodies (e.g., AbbVie (ABBV) with Humira) and other novel IBD therapies (e.g., Takeda (TAK) with Entyvio).
- SZN-043: A preclinical Wnt mimetic for potential use in liver diseases and other indications. It did not reach clinical trials. Market share data is not applicable as it was preclinical. Competitors in the liver disease space include companies developing treatments for NASH and other liver conditions (e.g., Gilead Sciences (GILD)).
Market Dynamics
Industry Overview
The regenerative medicine industry is focused on developing therapies that repair or replace damaged tissues and organs. It's a rapidly growing field driven by aging populations and increasing prevalence of chronic diseases.
Positioning
Prior to the acquisition, Surrozen aimed to be a leader in Wnt-mediated regenerative medicine. Its competitive advantage was its proprietary SWAPu2122 technology. The acquisition by Twin Ridge Capital Acquisition Corp has changed its positioning.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine is estimated to be in the tens of billions of dollars. Surrozen, being in early development, had the potential to capture a small portion of this TAM if its products had reached commercialization. Now, the company is under a new ticker with a new business objective.
Upturn SWOT Analysis
Strengths
- Proprietary SWAPu2122 technology platform
- Focus on Wnt signaling pathway
- Experienced management team (prior to acquisition)
- Strong preclinical data (prior to acquisition)
Weaknesses
- Preclinical stage of development
- High cash burn rate
- Reliance on Wnt signaling pathway
- Subject to Regulatory hurdles
- Recently Acquired
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in regenerative medicine technologies
- Accelerated regulatory pathways
Threats
- Competition from other regenerative medicine companies
- Failure to demonstrate clinical efficacy
- Regulatory setbacks
- Financial instability
- Change of strategy following acquisition
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- TAK
Competitive Landscape
Surrozen aimed to compete by offering novel regenerative medicine therapies based on the Wnt signaling pathway. The acquisition changes the competitive landscape of the company.
Growth Trajectory and Initiatives
Historical Growth: Growth was measured by the advancement of its pipeline and successful fundraising activities.
Future Projections: Future growth will depend on the strategic direction of Twin Ridge Capital Acquisition Corp.
Recent Initiatives: Recent initiative was its acquisition by Twin Ridge Capital Acquisition Corp.
Summary
Surrozen was a preclinical stage company developing novel regenerative medicine therapies targeting the Wnt signaling pathway. While its SWAPu2122 technology showed promise, the company faced significant financial and regulatory hurdles. The acquisition by Twin Ridge Capital Acquisition Corp changes the trajectory of the company. The current stock symbol is TRCA, representing the acquiring company's new business initiative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Industry reports
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information is accurate to the best of our knowledge as of the date of the analysis. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-01-11 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.